Latest Reported Offering
$25,750
Target Amount
$5,000,000
Maximum Amount
2024-10-31
Deadline
Security Details
Type: Common Stock
Price per share: $1.03
Price set by: per share
Shares offered: 25,750+
Offering Costs
Cash commission: 8.5%
of the total subscription proceeds, or $425,000 if all 4,854,368 shares of Common Stock are sold at the per share price of $1.03 per share.
Equity compensation: —
None
Filing history
Form C family — 1 filing| Filed | Form | File number | Portal | What it states | What the filer said |
|---|---|---|---|---|---|
| 2023-10-31 | C | 020-33135 | DealMaker Securities LLC | $25.8K target, up to $5M · Common Stock at $1.03 · closes 2024-10-31 | — |
The reported figures behind LexaGene Life Sciences CF Investors, Inc.
Form C prints a most-recent and a prior fiscal year side by side but never names them. The dashboard chains every filing into those years and plots them. EDGAR still has each Form C-AR; the dashboard lays every year they filed next to it.
- Reported financials chained into fiscal years — revenue, income, assets, cash — not one filing at a time
- A sparkline on each figure so the shape is visible before the numbers
- A revenue series dated to the filings that reported it
- The campaign as filed: target, ceiling, deadline, and the portal that ran it
- Follow it, and see it change on your watchlist
Company Information
Latest Metrics
Employees0
Total Assets$64,620
Cash on Hand$1,000.00
Revenues$0.00
Net Income$11,433
Crowdfunding Portals
The intermediary named in this company’s Form C filings. Investments in a Regulation Crowdfunding offering can only be made through them.